Bellerophon Therapeutics announced first patient treated in phase 3 clinical study of INOpulseᆴ inhaled nitric oxide therapy for COVID-19
On Jul. 13, 2020, Bellerophon Therapeutics announced that the first patient has initiated treatment in the Companyメs Phase…